title: Paracetamol (acetaminophen) with or without an antiemetic for acute migraine headaches in adults.
abstract: BACKGROUND
  This is an updated version of the original Cochrane review published in Issue 11, 2010 (Derry 2010). Migraine is a common, disabling condition and a burden for the individual, health services and society. Many sufferers choose not to, or are unable to, seek professional help and rely on over-the-counter analgesics. Co-therapy with an antiemetic should help to reduce nausea and vomiting, which are commonly associated with migraine.
  
  
  OBJECTIVE
  To determine the efficacy and tolerability of paracetamol (acetaminophen), alone or in combination with an antiemetic, compared with placebo and other active interventions in the treatment of acute migraine in adults.
  
  
  METHODS
  We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE and the Oxford Pain Relief Database for studies through 4 October 2010 for the original review, and to 13 February 2013 for the update. Two clinical trials registers (ClinicalTrials.gov and gsk-clinicalstudyregister.com) were also searched on both occasions.
  
  
  METHODS
  We included randomised, double-blind, placebo- or active-controlled studies using self-administered paracetamol to treat a migraine headache episode, with at least 10 participants per treatment arm.
  
  
  METHODS
  Two review authors independently assessed trial quality and extracted data. Numbers of participants achieving each outcome were used to calculate relative risk and numbers needed to treat (NNT) or harm (NNH) compared with placebo or other active treatment.
  
  
  RESULTS
  Searches for the update identified one additional study for inclusion. Eleven studies (2942 participants, 5109 attacks) compared paracetamol 1000 mg, alone or in combination with an antiemetic, with placebo or other active comparators, mainly sumatriptan 100 mg. For all efficacy outcomes paracetamol was superior to placebo, with NNTs of 12 (19% response with paracetamol, 10% with placebo), 5.0 (56% response with paracetamol, 36% with placebo) and 5.2 (39% response with paracetamol, 20% with placebo) for 2-hour pain-free and 2- and 1-hour headache relief, respectively, when medication was taken for moderate to severe pain.Paracetamol 1000 mg plus metoclopramide 10 mg was not significantly different from oral sumatriptan 100 mg for 2-hour headache relief; there were no 2-hour pain-free data.Adverse event rates were similar between paracetamol and placebo, and between paracetamol plus metoclopramide and sumatriptan. No serious adverse events occurred with paracetamol alone, but more serious and/or severe adverse events occurred with sumatriptan than with the combination therapy (NNH 32).
  
  
  CONCLUSIONS
  Paracetamol 1000 mg alone is statistically superior to placebo in the treatment of acute migraine, but the NNT of 12 for pain-free response at two hours is inferior to at of other commonly used analgesics. Given the low cost and wide availability of paracetamol, it may be a useful first choice drug for acute migraine in those with contraindications to, or who cannot tolerate, non-steroidal anti-inflammatory drugs (NSAIDs) or aspirin. The addition of 10 mg metoclopramide gives short-term efficacy equivalent to oral sumatriptan 100 mg. Adverse events with paracetamol did not differ from placebo; serious and/or severe adverse events were slightly more common with sumatriptan than with paracetamol plus metoclopramide.
authors: Pain Research and Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK. sheena.derry@ndcn.ox.ac.uk.
authors: Sheena
authors: S
authors: Derry
authors: R Andrew
authors: RA
authors: Moore
mesh_terms: D000082:Acetaminophen / Q000009:adverse effects / Q000627:therapeutic use*; D000208:Acute Disease; D000328:Adult; D018712:Analgesics, Non-Narcotic / Q000009:adverse effects / Q000627:therapeutic use*; D000932:Antiemetics / Q000009:adverse effects / Q000627:therapeutic use*; D004359:Drug Therapy, Combination / Q000379:methods; D006801:Humans; D012001:Hyperacusis / Q000188:drug therapy; D008787:Metoclopramide / Q000009:adverse effects / Q000627:therapeutic use; D008881:Migraine Disorders / Q000188:drug therapy*; D020795:Photophobia / Q000188:drug therapy; D016032:Randomized Controlled Trials as Topic; D018170:Sumatriptan / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D018712:Analgesics, Non-Narcotic; D000932:Antiemetics; D000082:Acetaminophen; D018170:Sumatriptan; D008787:Metoclopramide
references: Eur J Clin Pharmacol. 1983;24(6):777-85
references: 6884416
references: Cochrane Database Syst Rev. 2013 Apr 30;(4):CD008041
references: 23633350
references: Cephalalgia. 2004;24 Suppl 1:9-160
references: 14979299
references: Cephalalgia. 2000 Nov;20(9):765-86
references: 11167908
references: Eur J Neurol. 2009 Sep;16(9):968-81
references: 19708964
references: Headache. 2012 Apr;52(4):582-91
references: 22590713
references: Pharmacotherapy. 2003 Apr;23(4):494-505
references: 12680479
references: Cephalalgia. 1993 Apr;13(2):124-7
references: 8495454
references: Curr Opin Gastroenterol. 2008 May;24(3):287-97
references: 18408456
references: Br Med J. 1974 Nov 2;4(5939):265-8
references: 4425854
references: J Headache Pain. 2010 Aug;11(4):289-99
references: 20473702
references: Drugs. 1998 Nov;56(5):811-24
references: 9829155
references: Pain Pract. 2013 Mar;13(3):191-7
references: 22730906
references: Ugeskr Laeger. 1989 Sep 18;151(38):2436-8
references: 2678652
references: Headache. 2009 Apr;49(4):498-508
references: 19245386
references: Lancet. 2012 Dec 15;380(9859):2163-96
references: 23245607
references: Control Clin Trials. 1996 Feb;17(1):1-12
references: 8721797
references: Br Med J (Clin Res Ed). 1988 May 7;296(6632):1313-6
references: 3133061
references: Br J Clin Pract. 1985 Oct;39(10):388-92
references: 3907680
references: Am J Ther. 2000 Mar;7(2):99-114
references: 11319578
references: BMJ. 1995 Feb 18;310(6977):452-4
references: 7873954
references: Drug Saf. 2007;30(6):465-79
references: 17536874
references: Curr Med Res Opin. 2000;16(3):190-7
references: 11191009
references: BMJ. 2001 May 19;322(7296):1203-7
references: 11358770
references: Clin Infect Dis. 2000 Oct;31 Suppl 5:S202-10
references: 11113024
references: Br J Clin Pharmacol. 1975 Feb;2(1):57-63
references: 791318
references: Headache. 2010 May;50(5):819-33
references: 20236342
references: Nature. 1972 Dec 15;240(5381):410-1
references: 4564318
references: Cephalalgia. 2012 Apr;32(5):373-81
references: 22395797
references: Cochrane Database Syst Rev. 2010 Oct 06;(10):CD008039
references: 20927770
references: Value Health. 2009 Jan-Feb;12(1):55-64
references: 18671771
references: Cochrane Database Syst Rev. 2013 Apr 30;(4):CD008783
references: 23633360
references: BMJ. 1997 Sep 13;315(7109):635-40
references: 9310564
references: Proc Natl Acad Sci U S A. 2002 Oct 15;99(21):13926-31
references: 12242329
references: Pain. 2002 Jun;97(3):247-257
references: 12044621
references: Arch Intern Med. 2000 Dec 11-25;160(22):3486-92
references: 11112243
references: Headache. 2008 Jun;48(6):921-30
references: 18572432
references: Ann Intern Med. 1987 Aug;107(2):224-33
references: 3300460
references: Int J Epidemiol. 2002 Feb;31(1):140-9
references: 11914310
references: FASEB J. 2008 Feb;22(2):383-90
references: 17884974
references: J Headache Pain. 2012 Jul;13(5):361-78
references: 22644214
references: Rev Neurol. 2008 Nov 16-30;47(10):506-8
references: 19012253
references: Cephalalgia. 2005 Oct;25(10):776-87
references: 16162254
references: Headache. 2007 Mar;47(3):355-63
references: 17371352
references: Neurology. 2007 Jan 30;68(5):343-9
references: 17261680
references: Am J Ther. 2005 Jan-Feb;12(1):46-55
references: 15662292
references: J Epidemiol Community Health. 1997 Apr;51(2):175-9
references: 9196648
references: Cochrane Database Syst Rev. 2012 Feb 15;(2):CD008615
references: 22336849
references: Cochrane Database Syst Rev. 2010 Nov 10;(11):CD008040
references: 21069700
references: Neurology. 2005 Feb 8;64(3):463-8
references: 15699376
references: Cephalalgia. 2010 Sep;30(9):1065-72
references: 20713557
references: Cephalalgia. 1988;8 Suppl 7:1-96
references: 3048700
references: Headache. 2012 Jan;52(1):3-17
references: 22106869
references: Neurology. 2008 Aug 19;71(8):559-66
references: 18711108
references: Headache. 2006 May;46(5):715-25
references: 16643573
references: Headache. 1976 Jan;15(4):282-7
references: 1107267
references: Headache. 2009 Jan;49(1):79-89
references: 19125877
references: Pain. 1996 Aug;66(2-3):239-46
references: 8880846
references: J Headache Pain. 2005 Dec;6(6):429-40
references: 16388337
references: Dtsch Med Wochenschr. 1988 May 6;113(18):735-6
references: 3366070
references: Acta Neurol Scand. 1990 May;81(5):464-7
references: 2375249
references: J Headache Pain. 2013 Jan 10;14:1
references: 23566305
references: Pain. 1998 Dec;78(3):209-216
references: 9870574
references: Eur J Neurol. 2012 May;19(5):703-11
references: 22136117
references: Lancet. 2003 Mar 22;361(9362):981-2
references: 12660052
references: Med Klin (Munich). 1993 Nov 15;88(11):642-8
references: 8295604
references: Am J Ther. 2000 Mar;7(2):123-34
references: 11319580
references: Pain. 1997 Aug;72(1-2):95-7
references: 9272792